The Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor whose inactivation is implicated in the development of many human cancers, including breast carcinomas. Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors. Here, we show that RASSF1A inhibits breast cancer growth in vivo, and suppresses estrogen receptor (ERa) expression and function. Reconstitution of RASSF1A in MCF7 cells led to decreased ERa levels and reduced sensitivity to estrogen (E2). Concomitantly, we observed decreased expression of Id1 as well as the E2-responsive genes Bcl-2 and c-Myc that cooperatively contribute to the immortalization and transformation of breast epithelial cells. This downregulation was associated with induction of cell-cycle arrest and senescence that constitute early barriers to cancer initiation and progression. Knockdown of ERa showed that downregulation of ERa suffices to increase senescence and inhibit expression of Bcl-2, c-Myc and Id1. However, enforced expression of ERa only partially rescued RASSF1A-mediated growth inhibition and senescence, suggesting that suppression of ERa expression and activity is not the only mechanism by which RASSF1A inhibits growth and survival of breast cancer cells. Ectopic expression of Bcl-2, c-Myc and Id1 had little or no effect on RASSF1A-mediated growth arrest, indicating that RASSF1A acts dominantly over these oncogenes. Mechanistically, RASSF1A was found to suppress ERa expression through Akt1. It also transiently inhibited ERa-induced Ras-MAPK activity after exposure of cells to E2. Together, our data show that RASSF1A acts as a tumor suppressor in ERa þ mammary epithelial cells, in part through inhibiting ERa expression and activity. These findings suggest that RASSF1A has a key role in suppressing the transformation of human breast epithelial cells and ERa þ breast cancer initiation.
INTRODUCTION
Ras association domain family 1 isoform A (RASSF1A) is frequently inactivated in breast carcinomas, 1 and is associated with estrogen receptor (ERa þ ) status, as aberrant DNA methylation is thought to inactivate RASSF1A more frequently in ERa þ breast carcinomas. 2 --4 Furthermore, RASSF1A expression is lost in the ERa þ mammary carcinoma cell lines MCF7, T47-D and ZR75-1. 5 Moreover, inactivation of RASSF1A occurs early during the development of ER þ breast cancer and persists during cancer progression. 2 --4 Thus, RASSF1A inactivation might be an important and early event in the genesis of ERa þ breast cancer.
ERa is required for ductal elongation during mammary gland development. 6 It belongs to the steroid hormone receptor superfamily and functions as a ligand-activated transcription factor. In the nucleus, ERs undergo conformational changes upon interaction with estrogen (E2), allowing them to bind DNA and promote transcription of target genes. 7, 8 In addition to direct transcriptional effects, ERs localized to the plasma membrane can influence the activity of signalling pathways through coupling directly or indirectly to G-proteins by non-genomic mechanisms. 7 This leads to activation of downstream effectors such as protein kinase C-d, 9 mitogen activated protein kinase ERK (MAPK) 9, 10, 11 and phosphatidylinositol-3-OH kinase (PI3K). 12, 13 Thus, ERa is a key player in E2-mediated proliferation, survival and differentiation through regulating the transcription of E2-target genes as well as through activation of signal transduction pathways.
Many observations suggest an important role for ERa in breast cancer tumorigenesis. 14 In contrast to normal breast tissue where ERa þ cells are in the minority, overexpression of ERa is found in around 70% of human breast carcinomas.
14 Furthermore, ERa expression in benign breast epithelial lesions is a risk factor for breast malignancies, 15 whereas low ERa expression in normal breast tissue is associated with reduced breast cancer incidence. 16 In normal breast tissue, ERa expression and proliferation are inversely associated, indicating that ERa þ breast cells are nondividing, or that ERa is downregulated as cells enter the cell cycle. 17 This relationship is completely or partially lost in benign ERa þ breast lesions, where proliferating ERa þ cells are found. 18, 19 Thus, upregulation of ERa expression associated with enhanced proliferation might be an important and early event in the progression of precancerous lesions to breast cancer.
The proliferation of ERa þ cells in benign breast lesions and cancers may reflect an escape from apoptosis, cell-cycle arrest and senescence, barriers that suppress transformation and transition from precancerous hyperplasias into invasive cancer. 20, 21 At the molecular level, ERa mediates E2-dependent transcription of proto-oncogenes that counteract cell-cycle checkpoints, senescence and apoptosis. For example, the anti-apoptotic protein Bcl-2 is an E2-responsive gene 22 that is widely expressed in ERa þ tumors 23, 24 and correlates with recurrence following anti-hormonal therapies. 25 Bcl-2 also cooperates with c-Myc, ras and certain viral oncogenes during cell immortalization and transformation. 26, 27 c-Myc itself is an E2-responsive gene that induces cellcycle progression in breast cancer cells 28 through transcriptional repression of p21
Cip1/Waf1 , 29 and can transform immortalized breast epithelial cells in combination with either constitutive PI3K signalling or with constitutive Akt1 and Rac1 activity. 30 Expression of the helix-turn helix protein Id1 has been proposed to be regulated by E2, 31 although evidence for direct regulation is lacking. Id1 negatively regulates differentiation, stimulates G1-S phase progression through inhibition of p21 Cip1/Waf1(refs 32, 33) and p16
Ink4A
, 34 and suppresses senescence. 35 In addition, Id1 immortalizes embryonic fibroblasts in cooperation with Bcl-2. 36 Thus, a complex interplay of signalling pathways and oncogenes is required to transform breast epithelial cells, and E2-mediated gene expression might counteract mechanisms that normally suppress the initiation of breast cancer.
In this study, we hypothesized that RASSF1A may act as a tumor suppressor by regulating the expression and/or function of ERa. We found that reconstitution of RASSF1A in MCF7 cells led to decreased ERa levels, reduced expression of Id1 and the E2-responsive genes Bcl-2 and c-Myc, upregulation of p21
induction of cell-cycle arrest and senescence, and inhibition of signalling pathways involved in breast epithelial cell transformation. These data provide important mechanistic insights into how RASSF1A suppresses human breast cancer tumorigenesis.
RESULTS
RASSF1A inhibits E2-dependent outgrowth of orthotopic xenografts MCF7 is an ERa þ breast cancer cell line that is deficient for endogenous RASSF1A expression. 5 To determine whether RASS-F1A has a tumor-suppressive role in these cells, we developed MCF7 cells in which RASSF1A expression is inducibly restored in response to doxycycline ( Figure 1A) , then examined the effect of restored RASSF1A expression on E2-dependent growth of MCF7 tumors in vivo. To this end, 5 Â 10 6 MCF7 cells that conditionally express RASSF1A in response to doxycycline were implanted into the mammary fat pad of E2-substituted female NOD/SCID mice. Mice fed with doxycycline displayed a significant inhibition of orthotopic xenograft outgrowth in comparison with controls ( Figure 1B ). To verify RASSF1A expression upon doxycycline administration, sections of xenografts were stained for RASSF1A expression ( Figure 1C ). Doxycycline itself had no effect on the outgrowth of parental MCF7 tumors (Supplementary Figure 1) . Together, these data demonstrate that RASSF1A has a tumorsuppressive effect in this ERa þ breast cancer model. Accordingly, ductal and lobular epithelial cells in normal human breast tissue stained positively for RASSF1A ( Figure 1D ).
RASSF1A expression leads to growth inhibition, senescence and downregulation of ERa To determine whether RASSF1A has an effect on ERa expression, we treated the inducible RASSF1A-MCF7 cells with and without doxycycline. In response to RASSF1A expression, we observed downregulation of ERa and inhibition of growth, as evidenced by a reduced colony-forming ability (Figure 2a) . Similar results were obtained with doxycycline-induced expression of RASSF1A in T47D (Figure 2b ), another ERa þ breast cancer cell line that is deficient for endogenous RASSF1A expression. 5 These data indicate that RASSF1A-mediated downregulation of ERa is not cell line specific.
Conditional RASSF1A expression also led to an increase in G1 phase for both cell lines (Figures 2a and b , right panels) and to induction of senescence, as evidenced by increased senescenceassociated b-galactosidase (SAb-gal) activity (Figures 2c and d) . Figure 2) . Immunofluorescence double stainings revealed a reciprocal staining pattern for RASSF1A and ERa, consistent with negative regulation of ERa by RASSF1A (Figure 2e ). Collectively, these findings suggest that RASSF1A expression in ERa þ breast cancer cells causes reduced ERa expression, induction of cell-cycle arrest and senescence and reduced clonogenic survival.
RASSF1A expression leads to downregulation of E2-responsive genes that are positive regulators of G1-S phase progression and counteract senescence ERa mediates E2-dependent transcription of c-Myc and Bcl-2, genes that act together to protect cells from cell-cycle arrest, oncogene-induced senescence and apoptosis. E2 also has been reported to regulate Id1 expression. 31 We therefore hypothesized that loss of RASSF1A might cause inappropriate upregulation of ERa, in turn enhancing expression of these genes and thereby overriding transformation barriers. To investigate this hypothesis, we examined whether RASSF1A affects expression of ERa, Id1, c-Myc and Bcl-2. These experiments were performed in the presence of different E2 concentrations to allow effects on E2-dependent expression of these genes to be observed.
Using the doxycycline-inducible MCF7 cells, we found that RASSF1A-expressing cells display lower ERa protein and transcript levels in comparison with controls in the presence of all E2 concentrations used (Figures 3a and b; Supplementary Table 1) . The proteasome inhibitor Bortezomib strongly augmented RASS-F1A protein expression, yet levels of the ERa protein were unaffected by RASSF1A in the presence of Bortezomib (Figure 3c ), suggesting that RASSF1A may affect ERa protein levels in a proteasome-dependent manner.
RASSF1A-expressing MCF7 cells grown in the absence of E2 did not express Bcl-2 or activated c-Myc (Figure 3a ). However, Id1 was still present, indicating that its expression is E2 independent. We observed reduced protein expression of c-Myc and Bcl-2 in RASSF1A-expressing cells at all E2 concentrations used ( Figure 3a ; Supplementary Table 1) . Transcription of Bcl-2 and c-Myc but not Id1 was also significantly reduced upon expression of RASSF1A (Figure 3d ). RASSF1A expression in the inducible MCF7 cells in the presence and absence of E2 had no effect on expression of the ERa cofactor SRC3 (Supplementary Figure 3) , ruling this out as a potential mechanism for the observed effects on Bcl-2 and c-Myc transcription.
In addition to being downregulated by RASSF1A, we also found that E2 itself modestly downregulated ERa, and that this was associated with a concomitant increase in Bcl-2 expression (Supplementary Figure 4) , demonstrating an E2-dependent negative feedback loop on ERa expression. Nevertheless, RASSF1A expression substantially reduced levels of ERa over and above that induced by the presence of E2 (Figure 3a) .
To determine whether RASSF1A-mediated downregulation of ERa is sufficient to induce senescence and repress the expression of Id1, c-Myc and Bcl-2, we employed stable knockdown of ERa in The above findings are consistent with the notion that a consequence of RASSF1A expression in ERa þ breast cancer cells is induction of senescence through negative regulation of ERa, decreased E2-dependent oncogene expression and reduced cell survival. However, not all E2-responsive genes (for example, cyclin D1) were differentially regulated upon RASSF1A expression (Supplementary Figure 5) . Furthermore, Id1 protein levels were modulated by RASSF1A independently of E2 (Figure 3a ), but no effect of RASSF1A on Id1 transcription was observed (Figure 3d ). In control experiments, doxycycline treatment of parental MCF7 cells in the presence and absence of E2 had no effect on Id1 expression (Supplementary Figure 6) . These data suggest that RASSF1A can post-translationally regulate Id1 expression independently of E2.
RASSF1A inhibits cell growth and survival through ERa-dependent and independent mechanisms To determine whether ERa downregulation is the only mechanism by which RASSF1A mediates cell-cycle arrest and senescence, we established RASSF1A conditional MCF7 cells that ectopically express physiologically relevant levels of ERa constitutively. Upon induction of RASSF1A in these cells, levels of ERa remained equivalent to those in RASSF1A conditional MCF7 cells without doxycycline treatment (Figure 6a ), indicating that the cells maintain physiologically relevant levels of ERa in the presence of RASSF1A. Furthermore, western blot analysis showed increased Bcl-2 and c-Myc expression in the non-doxycycline-treated cells transfected with the ERa expression construct compared with controls, indicating functionality of the ectopically expressed ERa (Figure 6a ).
RASSF1A-induced downregulation of Bcl-2 was rescued when ERa expression levels were maintained ectopically at physiological levels ( Figure 6a ). However, c-Myc and Id1 expression was reduced and p21
Cip1/Waf1 levels were increased compared with those in RASSF1A-expressing MCF7 cells without ectopic ERa expression (Figure 6a ).
Ectopic expression of ERa in MCF7 cells in the absence of RASSF1A induction caused a slight decrease in colony-forming ability (Figure 6b ). In contrast, when RASSF1A was induced by doxycycline, MCF7 cells expressing ectopic ERa exhibited an increase in clonogenic survival, although colony formation was not rescued to the levels observed in the absence of RASSF1A (Figure 6b) . Similarly, RASSF1A-induced senescence was only moderately rescued by ectopic ERa expression (Figure 6c) . Furthermore, even though knockdown of ERa resulted in increased p21
Cip1/Waf1 levels (Figure 4a ), MCF7 cells conditionally expressing RASSF1A displayed increased p21
Cip1/Waf1 levels in both the presence and absence of enforced ERa expression (Figure 6a ), again indicating that ectopic ERa expression does not completely rescue the effect of RASS1A on p21
Cip1/Waf1 levels. Collectively, these findings suggest that RASSF1A exerts its tumor suppressor function only partially through downregulation of ERa expression.
We also tested whether high E2 concentrations counteracts RASSF1A-mediated growth inhibition and induction of senescence. However, this was not the case (Figure 6d) .
Finally, we determined whether Id1, Bcl-2 and c-Myc have the potential to combat RASSF1A-mediated growth inhibition. Neither ectopic overexpression of Id1 alone or in combination with Bcl-2, nor overexpression of c-Myc was able to circumvent RASSF1A-mediated inhibition of clonogenic survival ( Supplementary  Figures 7a and b) . Although enforced expression of Bcl-2 and c-Myc together increased cellular survival in the presence and absence of RASSF1A expression, the relative difference between RASSF1A-expressing and non-expressing cells was not significantly different to control cells (Supplementary Figure 7b RASSF1A inhibits ERa expression via Akt1, and counteracts mechanisms that lead to E2-independent growth A variety of mechanisms that confer E2-independent growth and in turn resistance against drugs that target ERa have been identified, including constitutive activation of Akt1 and 3 (refs 37,38) and hyperactivation of the Ras-MAPK pathway. 39 As RASSF1A is able to modulate the MAPK pathway and inhibit Akt, 40 we next investigated whether RASSF1A might regulate signalling pathways associated with E2 independence.
First, we established RASSF1A conditional MCF7 cells that express MyrAkt1 or MyrAkt3, 37 ,38 myristylated forms of Akt1 and Akt3 that localize to the plasma membrane and are therefore activated. In agreement with our previous findings, 40 conditional expression of RASSF1A inhibited MyrAkt1 and MyrAkt3 through phosphorylation at Ser 473 ( Figure 7a , right blot). Accordingly, while expression of either MyrAkt1 or MyrAkt3 supported outgrowth of the cells under E2-free conditions, neither MyrAkt1 nor MyrAkt3 was able to relieve RASSF1A-mediated growth inhibition as measured by colony formation (Figure 7b) .
Molecularly, we found that MyrAkt1 inhibited RASSF1A-mediated ERa downregulation, whereas MyrAkt3 had no such effect (Figure 7a, right blot) . Moreover, MyrAkt1-expressing MCF7 cells displayed a higher clonogenic survival under E2-free conditions in comparison with their MyrAkt3-expressing counterparts (Figure 7b ). These findings point to a potential interplay between Akt1 and either ERa expression or protein stabilization. Accordingly, conditional MCF7 cells grown in the absence of doxycycline exhibited decreased expression of endogenous ERa when incubated with the PI3K inhibitor Ly294.002 (Figure 7c) . Furthermore, while reduced colony formation consequent to chemical ablation of ERa protein by fulvestrant was substantially rescued by MyrAkt1 (Figure 7d ), this rescue was abrogated by RASSF1A (Figure 7e ). Collectively, these findings indicate that RASSF1A downregulates ERa through inhibition of Akt1 activity, and that RASSF1A inhibits E2-independent growth.
Next, we investigated whether RASSF1A-mediated downregulation of ERa also requires modulation of the Ras-MAPK pathway. First, control experiments were performed to demonstrate that doxycycline in parental MCF7 cells had no effect on E2-induced ERK phosphorylation (Supplementary Figure 8) . Next, when conditional MCF7 cells were grown in the absence of doxycycline and treated with the MEK inhibitor UO126, decreased expression of endogenous ERa was observed (Figure 7c) . Furthermore, RASSF1A suppressed the enhanced ERK phosphorylation observed 35 min after treatment with E2 (Figure 7f) , consistent with the notion that RASSF1A-dependent suppression of E2-mediated activation of the Ras-MAPK pathway might be involved in the regulation of ERa. However, when conditional MCF7 cells were cultured in the presence of E2 for 24 h, RASSF1A expression promoted sustained ERK phosphorylation (Figure 7a , right blot), indicating that RASSF1A can also negatively regulate ERa levels independently of ERK phosphorylation. Accordingly, inhibition of PI3K activation led to downregulation of ERa, despite concomitant activation of the Ras-MAPK pathway (Figure 7c ).
DISCUSSION
Here we show that RASSF1A can exert a tumor-suppressive activity in breast cancer cells in two ways. First, it can negatively regulate ERa levels, leading to inhibition of signal transduction pathways that are activated by E2 and thus decreased E2-dependent expression of oncogenes that can override transformation barriers such as senescence and apoptosis. Second, RASSF1A inhibits signalling pathways involved in E2-independent growth that are involved in the transformation of breast epithelial cells. These results therefore identify RASSF1A expression as a barrier that suppresses transformation of breast epithelial cells.
A major finding of this paper is that RASSF1A expression downregulates ERa, implying that loss of RASSF1A during tumor development serves to increase ERa levels. Increased ERa expression and function can make cells more susceptible to E2-induced stimulation of proliferation and are thought to be an initial, important event during breast carcinogenesis. 15,17--19 Enhanced ERa levels may act by endowing tumor cells with a more robust response to E2. Furthermore, the response to E2 may be qualitatively different, as the mechanism of transactivation and target gene regulation differ when ERa levels are enhanced. 41 A variety of mechanisms enhance ERa levels, including amplification of the ERa gene, although almost half of breast tumors with high ERa do not show such an amplification. 42 Mutation of caveolin-1 (ref. 43) and loss of expression of miR206 (ref. 44) have also been implicated in enhancing ERa expression in breast cancer cells. Here, we present a novel mechanism namely that loss of RASSF1A can also contribute to enhanced ERa levels. We suggest that RASSF1A expression in non-transformed cells serves to restrict the levels of ERa through inhibiting Akt1. Furthermore, RASSF1A also blocked early E2-mediated activation of the Ras-MAPK pathway, and chemical inhibition of ERK phosphorylation caused ERa downregulation, identifying a further possible mechanism by which RASSF1A can suppress ERa expression. However, this latter mechanism appears to operate only transiently, as RASSF1A caused sustained ERK phosphorylation following prolonged exposure of cells to E2. Inhibition of PI3K activation was sufficient to downregulate ERa even though the Ras-MAPK pathway was activated.
Our findings indicate that RASSF1A-mediated inhibition of Akt1 serves to reduce either ERa expression or protein stability. These observations are consistent with studies using transgenic animals that express MyrAkt1 in the mammary epithelium, in which Akt1 activity results in increased expression of ERa during carcinogeninduced mammary tumorigenesis. 45 MyrAkt1 was shown to induce E2-independent outgrowth and tamoxifen resistance of breast cancer cells. 37 Our data suggest that by inhibiting Akt1, RASSF1A serves as a transformation barrier in breast epithelial cells that acts in part at the level of ERa, in part through E2-independent mechanisms. A consequence of RASSF1A-mediated suppression of ERa is reduced expression of E2-dependent genes such as Bcl-2 and c-Myc. Although Id1 has been reported to be E2 regulated, 31 we observed no effect of E2 on Id1 expression at either the protein or the transcriptional levels. Nevertheless, both knockdown and chemical ablation of ERa reduced expression of Id1. How this is achieved remains unclear, but we note that ERb has been reported to directly bind to Id1. 46 If ERa also complexes with Id1, then it is conceivable that the stability of Id1 may thereby be enhanced in an E2-independent manner. In further studies, we will investigate if this is the case.
We show that RASSF1A inhibits initial E2-mediated activation of the Ras-MAPK pathway (Figure 7f ), whereas after 24 h exposure to E2, RASSF1A enhances ERK phosphorylation (Figure 7a , left panel, lanes 2 and 4). This latter effect is also observed in the absence of E2, albeit to a lesser extent (Figure 7a, left panel, lanes 1 and 2) . E2 treatment has been reported to lead to rapid and transient activation of the Ras-MAPK pathway that is thought to proceed through a multistep process involving E2-bound ERa, Src and the p85 regulatory subunit of PI3K. 11, 13, 47, 48 In turn, Src mediates activation of matrix metalloproteinases that liberate HB-EGF bound to the surface of the MCF7 cells, leading to epidermal growth factor receptor transactivation and activation of Ras-MAPK pathway. 11 Our results are consistent with the notion that RASSF1A suppresses E2-mediated liberation of membrane-bound HB-EGF, in turn inhibiting the rapid and transient activation of the Ras-MAPK pathway (Figure 8 ). On the other hand, Akt activity inhibits Raf signalling in MCF7 cells. 49 As expression of RASSF1A inhibits Akt activity, Akt-mediated inhibition of Raf would thereby be relieved, resulting in enhanced ERK phosphorylation. This effect would be more pronounced in the sustained presence of E2 as ERa is downregulated, further reducing Akt activity. Future work will aim to provide experimental substantiation for this notion.
In previous studies, we have demonstrated that RASSF1A executes cell-cycle arrest and senescence in lung cancer cells through p21
Cip1/Waf1 upregulation in a p53-independent manner. 40 In this report, we demonstrate that RASSF1A has the ability to upregulate p21 Cip1/Waf1 in ERa þ breast cancer cells through downregulation of ERa. Id1 and c-Myc are negative regulators of p21 Cip1/Waf1(refs 29, 33) and are also downregulated by RASSF1A. However, RASSF1A was able to upregulate p21
Cip1/Waf1 even in the context of enforced expression of ERa or c-Myc. Thus, additional mechanisms in addition to downregulation of ERa and E2-target genes contribute to RASS1A-mediated upregulation of p21 Cip1/Waf1 . In lung cancer cells, RASSF1A-mediated p21
Cip1/Waf1 upregulation is dependent on Akt inhibition, 40 and thus the inhibition of Akt activity we observed in MCF7 cells in response to RASSF1A expression is likely to account at least in part for the ERa-independent upregulation of p21
Cip1/Waf1 . Our data suggest that RASSF1A suppresses transformation of breast cancer cells through the regulation of several signalling pathways (Figure 8 ), contributing to our understanding of the . Consistently, c-Myc can transform immortalized early passage human breast epithelial cells either together with constitutive PI3K signalling or in combination with constitutive Akt1 and Rac1. 30 When RASSF1A is expressed, Akt1 activation is suppressed, leading to inhibition of ERa expression, and reduced transcription of E2-dependent oncogenes. This leads to upregulation of p21 Cip1/Waf1 and induction of senescence.
Collectively, these findings suggest that RASSF1A has a central role in suppressing transformation of human breast epithelial cells through ERa-dependent and independent mechanisms that serve to activate early barriers to transformation such as senescence. Our data therefore shed important new light onto how RASSF1A acts as a tumor suppressor during the genesis of ERa þ breast tumors.
MATERIALS AND METHODS

Plasmids and reagents
A FLAG-tagged human RASSF1A cDNA was cloned into the retroviral vector pRevTRE (Clontech, Mountain View, CA, USA) to allow conditional transgene expression controlled by doxycycline in the presence of rt TA. 40 Lentiviral shRNA constructs pLKO.1 CMV tGFP ESR1K.O 1 and 2 and scramble were purchased from Sigma-Aldrich (Taufkirchen, Germany). A cDNA encoding human ERa was cloned into the retroviral vector pQCXIN (Clontech). pBabe-neo, pBabe-Neo-Myr-Flag-AKT1 (ref. 50) and pWZL Neo Myr Flag AKT3, 50 pQCXIN-ERa, pBabe-neo-Id1 and pMIG Bcl-2 (ref. 51) and pWZL Blast myc 52 were used for transduction of RASSF1A-MCF7. E2 (17-estradiol), fulvestrant and doxycycline were purchased from Sigma-Aldrich. UO126 and LY294.002 were purchased from Calbiochem (Nottingham, UK). Antibodies against ERa, Bcl2, c-Myc, Id1, p21, ERK1, Akt and b-actin were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Antibodies against p-Akt Ser473 and p-44/42 Erk1/2 were from CST (Danvers, MA, USA), and the anti-RASSF1A antibody was from Abcam (Cambridge, UK).
Cell culture and viral transduction MCF7 and T47D were purchased from ATCC. Unless otherwise indicated, parental cell lines were maintained in RPMI supplemented with 10% fetal bovine serum (tetracycline-free fetal bovine serum (Tet-approved FBS, Clontech) for conditional cells), 1% L-glutamine and 1% penicillin/ streptomycin. The packaging cell lines Phoenix GP and HEK293T were used for generation of retro-or lentiviruses following standard calcium phosphate protocols. MCF7 and T47D cells were transduced using the retroviral vectors pRevTRE (containing the human RASSF1A cDNA) and pQCXIP (containing rtTA-M2) 53 as previously described. 40 Cells were selected with puromycin and hygromycin. For all experiments, pooled transduced selected cells rather than single cell clones were used unless otherwise indicated. Conditional RASSF1A expression was achieved by addition of doxycycline (1 mg/ml). 
Other methods
Western blot analysis, fluorescence-activated cell sorting analysis, detection of SAb-gal-positive cells and clonogenic assays were performed as previously described. 40 Quantitative RT --PCR was performed with Sybr Green (Invitrogen) according to manufacturer's instructions. The primers used are listed in Supplementary Information.
Immunohisto-and immunofluorescence staining
Paraffin-embedded samples of human breast tissue were obtained from the Department of Obestrics and Gynecology, Johannes Gutenberg 
